Hepamerz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528l-Ornithine%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520l-Aspartate%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520-%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520lola%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

# Hepamerz (l-Ornithine l-Aspartate) ## Overview Hepamerz is a combination of the amino acids l-ornithine and l-aspartate. It is thought to reduce ammonia levels in the blood by promoting its detoxification in the liver and extrahepatic tissues. ## Primary Indications Treatment of latent and manifest hyperammonemia associated with liver disease (e.g., cirrhosis) to improve symptoms of hepatic encephalopathy. ## Adult Dosing * **Oral:** 3 to 6 g three times daily. The total daily dose should not exceed 18 g. * **Intravenous:** Typically 5 g to 10 g infused over 30 to 60 minutes, up to three times daily. Specific IV dosing and duration depend on the severity of hyperammonemia and patient response, and may be guided by local protocols. ## Pediatric Dosing * **Oral:** Dosing in children is not well established and should be individualized based on age, weight, and clinical response. Some sources suggest 100-200 mg/kg/day divided into 3 doses, but this is not universally accepted. * **Intravenous:** Not established. ## Dose Adjustments No specific dose adjustments are required for renal or hepatic impairment beyond the underlying condition for which the drug is prescribed. ## Contraindications * Hypersensitivity to l-ornithine, l-aspartate, or any component of the formulation. * Severe kidney disease (renal failure). ## Adverse Effects Commonly reported adverse effects include nausea, vomiting, abdominal discomfort, and diarrhea. Transient skin irritation has been reported with IV administration. ## Key Drug Interactions No significant drug interactions have been consistently reported. ## Monitoring * Monitor ammonia levels. * Monitor for signs and symptoms of hepatic encephalopathy. * Assess for gastrointestinal side effects. ## Clinical Pearls * Hepamerz is primarily used as an adjunct therapy for hepatic encephalopathy. * Oral administration may be more effective when taken with meals. * The efficacy of Hepamerz in pediatric patients is not well-defined. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and relevant clinical guidelines for the most current and comprehensive details before making any clinical decisions.